Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab q12 weeks vs q3 weeks in NSCLC with clinical benefit to pembrolizumab monotherapy
KCT0004269Phase 2Withdrawn
- Sponsor
- Ministry of Health & Welfare
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Ministry of Health & Welfare. Planned start Jan 2024; status: withdrawn.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0004269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004269.